Show simple item record

dc.contributor.authorSchmidt, Leah Marie
dc.contributor.authorEskiocak, Banu
dc.contributor.authorKohn, Ryan
dc.contributor.authorDang, Celeste
dc.contributor.authorJoshi, Nikhil
dc.contributor.authorDuPage, Michel J.
dc.contributor.authorLee, Da-Yae
dc.contributor.authorJacks, Tyler E
dc.date.accessioned2020-06-25T18:10:33Z
dc.date.available2020-06-25T18:10:33Z
dc.date.issued2019-08
dc.date.submitted2019-03
dc.identifier.issn0027-8424
dc.identifier.issn1091-6490
dc.identifier.urihttps://hdl.handle.net/1721.1/125983
dc.description.abstractNatural killer (NK) cells inhibit tumor development in mouse models and their presence in tumors correlates with patient survival. However, tumor-associated NK cells become dysfunctional; thus, stimulation of NK cells in cancer is emerging as an attractive immunotherapeutic strategy. In a mouse model of lung adenocarcinoma, NK cells localized to tumor stroma with immature phenotypes and low functional capacity. To test their responsiveness within established disease,we engineered a system for inducible expression of activating ligands in tumors. After stimulation, NK cells localized inside tumors, with increased cytokine production capacity. Strikingly, T cells were also recruited to tumors in an NK cell-dependent manner, and exhibited higher functionality. In neoantigen-expressing tumors, NK cell stimulation enhanced the number and function of tumor-specific T cells and, in long-term settings, reduced tumor growth. Thus, even in established disease NK cells can be activated to contribute to antitumor immunity, supporting their potential as an important target in cancer immunotherapy.en_US
dc.description.sponsorshipNational Institutes of Health (Grant U54 CA126515-01)en_US
dc.description.sponsorshipNational Institutes of Health (Grant R01-CA185020-01)en_US
dc.language.isoen
dc.publisherNational Academy of Sciencesen_US
dc.relation.isversionofhttp://dx.doi.org/10.1073/pnas.1904253116en_US
dc.rightsArticle is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.en_US
dc.sourcePNASen_US
dc.titleEnhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulationen_US
dc.typeArticleen_US
dc.identifier.citationSchmidt, Leah et al. "Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation." Proceedings of the National Academy of Sciences 116, 35 (August 2019): 17460-17469 © 2019 National Academy of Sciencesen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biologyen_US
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MITen_US
dc.relation.journalProceedings of the National Academy of Sciencesen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2019-12-10T18:41:31Z
dspace.date.submission2019-12-10T18:41:33Z
mit.journal.volume116en_US
mit.journal.issue35en_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record